

Embedding the patient voice in the centre of a national quality improvement programme


Learning from the National Cancer Audit Collaborating Centre (NATCAN)

22nd June 2026



Housekeeping

- The webinar will be recorded and available on the NATCAN website
- Microphones are automatically switched off
- Questions will take place at the end of the session (rather than following each individual presentation)
- Please post your questions for the team in the Q&A box during the webinar



9.30 – 9.35: **Introduction**

Chris Carrigan, Data Advisor, Use My Data (Chair)

9.35 – 9.45: **NATCAN – who we are and what we do**

- Julie Nossiter, Director of Operations, NATCAN



9.45 – 9.50: **Establishing Patient & Public Involvement (PPI) Forums across NATCAN**

- Verity Walker, Project Manager, NATCAN




9.50 – 9.55: **Living beyond pancreatic cancer**

- Christine Ashworth, National Pancreatic Cancer Audit (NPACA) PPI Forum
- ***Video produced in collaboration with Pancreatic Cancer UK***




9.55 – 9.10: **Working with the National Lung Cancer Audit (NLCA) PPI Forum**

- Lauren Dixon, NLCA Clinical Fellow



10.10 – 10.20: **Experience of working with NATCAN and the National Non-Hodgkin Lymphoma Audit (NNHLA)**

- Frank Burroughs, NNHLA PPI Forum Chair



10.20 – 10.25: **Setting up NATCAN's Patient Involvement Network (PIN)**

- Vikki Hart, Senior Project Manager, NPaCA and NNHLA



10.25 – 10.30: **Q&A**

- Chris Carrigan, Use My Data (Chair)

National Cancer Audit Collaborating Centre (NATCAN) – who we are and what we do

22nd June 2026

Julie Nossiter, Director of Operations, NATCAN & Assoc Prof Cancer Services Research (Hon), LSHTM



NATCAN

National Cancer Audit
Collaborating Centre

What is National Clinical Audit?

- Checks whether patients are receiving care that meets agreed standards and guidelines
- Uses NHS data to see how care is delivered
- Identifies what is working well and where improvement is needed
- Allows hospitals to compare their care with others (benchmarking)
- Helps improve safety, quality and outcomes for patients
- Shares learning across the NHS so patients everywhere benefit



National Cancer Audit Collaborating Centre (NATCAN)

NATCAN aims to:

1. Provide **regular, timely** evidence to cancer services of **variations in care** in England & Wales
2. Identify **reasons for the variation** in care and help guide **quality improvement** initiatives
3. **Stimulate improvements** in cancer detection, access to treatment and outcomes

Commissioned by HQIP and funded by NHSE and the Welsh Government initially for 3 years, now extended to 30.09.27

Home of the ten national cancer audits in England & Wales

- Kidney Cancer  **NKCA**
National Kidney Cancer Audit
- Non-Hodgkin Lymphoma  **NNHLA**
National Non-Hodgkin Lymphoma Audit
- Ovarian Cancer  **NOCA**
National Ovarian Cancer Audit
- Pancreatic Cancer  **NPaCA**
National Pancreatic Cancer Audit
- Primary &  **NAoPri**
National Audit of Primary Breast Cancer
- Metastatic Breast Cancer  **NAoMe**
National Audit of Metastatic Breast Cancer
- Lung Cancer  **NLCA**
National Lung Cancer Audit
- Oesophago-Gastric Cancer  **NOGCA**
National Oesophago-Gastric Cancer Audit
- Bowel Cancer  **NBOCA**
National Bowel Cancer Audit
- Prostate Cancer  **NPCA**
National Prostate Cancer Audit



NATCAN: key features

- Close **clinical-methodological partnership**
- Close links with all **stakeholder groups**
 - Clinical professional bodies
 - People with lived experience, charities
 - NHS commissioners & regulators
- Use of routine, **national (existing and linked) datasets** only
 - Public reporting of results
- Audit delivery & **Quality improvement informed by research & development**



Who we are: June 2026



NATCAN

National Cancer Audit
Collaborating Centre

HEALTHCARE QUALITY IMPROVEMENT PARTNERSHIP

Clinical Effectiveness Unit-RCSEng

NATIONAL CANCER AUDIT COLLABORATING CENTRE (NATCAN)

NATCAN Board

Chair, HQIP, NHS England, Welsh Government, RCR, Macmillan Cancer Support, NDRS, WCN, RCSEng Patient & Public Group, NATCAN Executive

NATCAN Executive Team

Director of Operations (Julie Nossiter), Clinical Director (Tom Roques),
Director CEU (David Cromwell),
Senior Statistician (Kate Walker),
Senior Clinical Epidemiologist (Jan van der Meulen)

**QUALITY IMPROVEMENT
TEAM**
(working with all cancer audits)

PPI FORUMS
(one for each cancer audit)

**CLINICAL REFERENCE /
ADVISORY GROUPS**
(one for each cancer audit)

Centre-level team members:
Project Manager (Verity Walker),
Quality Improvement Clinical Fellow (Sugeeta Sukumar),
Data Manager (Abhishek Dixit),
Project Coordinators (Faine Chan, Aurelia Chen)

CEU: NVR & Crane / health services projects

LSHTM: NIHR, MRC funded
health services research

NHSE/ National Disease Registration Service
Digital Health and Care Wales/Wales

Lung	Prostate	Bowel	OG	Primary Breast	Metastatic Breast	Pancreatic	Kidney	Ovarian	Non-Hodgkin Lymphoma
Clinical leads: Neal Navani (Respiratory medicine), Doug West (Surgery, SCTS), John Conibear (Oncology, RCR) Senior Methodologist: David Cromwell/ Methodologist: Sarah Cook Statistician/Data Scientist: Adrian Cook, Jessica Thomas Clinical Fellow: Lauren Dixon Audit Manager/Coordinator: Joanne Boudour/ Faine Chan	Clinical leads: Alison Tree (Oncology, BUG), Noel Clarke (Surgery, BAUS) Senior Methodologist: Jan van der Meulen, Statistician/Data Scientist: Adrian Cook, Emily Mayne Clinical Fellows: Arjun Nathan, Justin Liu, Matt Parry Audit Manager/Coordinator: Aurelia Chen	Clinical leads: Mike Braun (Oncology, ACP), Nicola Fearnhead (Surgery, ACPGBI) Senior Methodologists: Kate Walker Methodologist: Sarah Cook Clinical Fellow: Adil Rashid, Leo Watton Statistician/Data Scientist: Angela Kuryba Audit Manager/Coordinator: Karen Darley/ Augusto Nembrini	Clinical leads: Nigel Trudgill (Gastroenterology, BSG), James Gossage (Surgery, AUGIS), Tom Crosby/Betsan Thomas Senior Methodologist: David Cromwell Methodologist: Min Hae Park Statistician/Data Scientist: Amanda McDonnell Clinical Fellow: Olivia O'Connor Audit Manager/Coordinator: Karen Darley/ Augusto Nembrini	Clinical leads: David Dodwell (Oncology, UKBCG), Keiran Horgan (Surgery, ABS) Senior Methodologist: David Cromwell Methodologist: Diana Withrow Clinical Fellows: Jemma Boyle, Sarah Blacker, Liyang Wang Statistician/Data Scientist: Christine Delon Audit Manager/Coordinator: Robert Deuce/ Augusto Nembrini	Clinical leads: David Dodwell, Keiran Horgan, Mark Verill (Medical Oncology, UKBCG) Senior Methodologist: David Cromwell Methodologist: Diana Withrow Clinical Fellows: Jemma Boyle, Georgina Hanbury, Liyang Wang Statistician/Data Scientist: Christine Delon Audit Manager: Robert Deuce/ Augusto Nembrini	Clinical leads: Nigel Trudgill (Gastroenterology, BSG), Andrew Smith (Surgery, BAUS), Ganesh Radhakrishna (RCR) Senior Methodologist: David Cromwell Methodologist: Min Hae Park Clinical Fellow: Suzi Nallamilli Statistician/Data Scientist: Amanda McDonnell Audit Manager/Coordinator: Vikki Hart/ Faine Chan	Clinical leads: Amit Bahl (Oncology, BUG), Grant Stewart (Surgery, BAUS) Senior Methodologist: Jan van der Meulen, Clinical Fellow: Raghav Varma Statistician/Data Scientist: Emily Mayne, Will Cunningham Audit Manager/Coordinator: Aurelia Chen	Clinical leads: Agnieszka Michael (Medical Oncology, BGCS) Currently recruiting (Surgery, BGCS). Senior Methodologists: Jan van der Meulen, Ipek Guroi Urganici Methodologist: Andrew Hutdhings Clinical Fellow: Georgia Zachou Audit Manager/Coordinator: Joanne Boudour/ Aurelia Chen	Clinical leads: Cathy Burton (Haematology, BSH) David Cutter (Oncology, BSH) Senior Methodologists: Kate Walker, Methodologist: Lu Han Clinical Fellow: Ruhi Kanani Statistician/Data Scientist: Kit Ying Yuen, Louise Reynolds Audit Manager/Coordinator: Vikki Hart/ Faine Chan

ABS, Association of Breast Surgery; ACPGBI, Association of Coloproctology of Great Britain and Ireland; AUGIS, Association of Upper Gastrointestinal Surgeons; BAUS, British Association of Urological Surgeons; BSG, British Society of Gastroenterology; BSH, British Society of Haematology; BUG, British Uro-oncology Group; CEU, Clinical Effectiveness Unit; HQIP, Healthcare Quality Improvement Partnership; LSHTM, London School of Hygiene & Tropical Medicine; MRC, Medical Research Council; NHSE, National Health Service England; NIHR, National Institute for Health and Care Research; NVR, National Vascular Registry; UKBCG, UK Breast Cancer Group; RCR, Royal College of Radiologists; RCSEng, Royal College of Surgeons of England; SCTS, Society for Cardiothoracic Surgery.



NATCAN

National Cancer Audit
Collaborating Centre

Working closely with patient charities





NATCAN

National Cancer Audit
Collaborating Centre

Audit PPI Forums

People and communities using health and care services are best placed to understand what they need, what is working and what could be improved ¹

- Lived experience is as valuable as clinical expertise in shaping health and care services
- Established for each audit, working collaboratively with patient charities



NATCAN

National Cancer Audit
Collaborating Centre

NATCAN: progress so far

First year (from Oct 2022)

- Establish **organisational & governance structures**
- Develop NATCAN **communication strategy**
- Creation of **common data access channels**
- Establish **6 'new' audits**
- Move **4 'existing' audits** into NATCAN
- Recruitment for **PPI Forums**
- Audit **scoping & development**

Second year (from Oct 2023)

- Develop NATCAN **Quality Improvement (QI) plans** for each audit
- **Reporting & feedback** of audit results begins (quarterly & annual)

Third year onwards (from Oct 2024)

- Apply for & secure **two-year extension of funding**
- Develop & iterate **data dashboard**
- Design & roll out of **QI interventions**

Personal View

The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales



Ajay Aggarwal, David Cromwell, Julie Nossiter, Jan van der Meulen, Kate Walker, on behalf of the NATCAN audit teams*

The National Cancer Audit Collaborating Centre (NATCAN) was launched on Oct 1, 2022, and is delivering ten national cancer audits to assess and assure the quality of National Health Service (NHS) cancer care in England and Wales. These audits are a collaboration between clinical leaders, methodological experts, professional organisations, civil society, and policy makers to develop and implement performance measures across all NHS cancer care and inform quality improvement of the care pathway. The aims of NATCAN are to provide transparent and timely feedback to hospitals about their practices and outcomes of cancer care, identify opportunities for improvement of cancer care, and support hospitals to conduct quality-improvement initiatives. The key methods used to achieve these aims were use of routinely collected data that did not necessitate bespoke collection by health-care staff specifically for the audit; public reporting of outcomes of care at hospital and regional levels; assessment of determinants of variation in cancer care to target quality improvement; and a central governance structure to ensure that unsafe care or outlying performance were managed effectively and promptly. This Personal View provides comparisons between NATCAN and other international audit programmes, including how other countries could consider and incorporate components of NATCAN, alongside scope for future development.

Introduction

Cancer-survival outcomes in the UK are worse than other countries with similar economic profiles.¹ In the UK and internationally, there is wide variation across hospitals in who receives evidence-based treatments and in outcomes for patients receiving the same treatment across different types of cancer.^{2,4} In response, the National Cancer Audit Collaborating Centre (NATCAN), a new national centre of excellence, was launched on Oct 1, 2022, to assess and assure the quality of National Health Service (NHS) cancer care in England and Wales

performance indicators, formulation of audit recommendations, and identification of priorities for quality improvement. Each audit has a patient and public involvement forum with representation of people with lived experience of cancer and a clinical reference group whose members included clinical experts, professional organisations, NHS policy makers, providers of cancer registry and hospital administrative datasets, and patient charities, ensuring that all activities and outputs reflect priorities across all stakeholders.

The aims and objectives of each audit are consolidated

Lancet Oncol 2025; 26: e225-32

*Members listed in the appendix

Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK

(Prof A Aggarwal MD PhD, Prof D Cromwell PhD, J Nossiter PhD)

(Prof J van der Meulen PhD, Prof K Walker PhD), Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK

(Prof A Aggarwal), Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK (Prof D Cromwell, J Nossiter, Prof J van der Meulen, Prof K Walker)

Correspondence to: Prof Ajay Aggarwal, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK

ajay.aggarwal@lshtm.ac.uk

See Online for appendix

NATCAN Quality Improvement Plans

- Summer 2023 - Scoping Exercise
 - What are the major quality issues?
 - Defined the scope and care pathway for the 'new' cancer audits, refreshed for 'established' audits
- Spring 2024 – Continued this work to develop Quality Improvement (QI) Plans
 - Defined 5 QI goals & 10 Performance Indicators (metrics)
 - What is **measurable** with the data, and does it relate to the quality issue?
 - Is it **actionable**? Will we see any variation? Does it reflect potential deficits in the quality of care?
 - What can be done about the quality issue – is it **improvable**?

Published September 2024

NATCAN publishes Quality
Improvement Plans



05.09.24

Use of routine, existing, linked NHS data

What information is used?

- Diagnosis and stage of cancer
- Treatments (surgery, chemotherapy, radiotherapy)
- Other health conditions
- Hospital stays, readmissions and complications



All patient identifiable information is removed (name, NHS number, date of birth, address, post code) before information is securely transferred to NATCAN



Use of routine, existing, linked NHS data



NATCAN

National Cancer Audit
Collaborating Centre

England (annual & quarterly)

Cancer Outcomes and Services Dataset (COSD)

Cancer Registration data (NCRD*/RCRD)

Hospital Episode Statistics (HES)

Systemic Anti-Cancer Therapy (SACT) dataset

National Radiotherapy Dataset (RTDS)

Mortality data - Office for National Statistics (ONS)

Medicines Dispensed in Primary Care (NHSBSA)*

Somatic Molecular Testing Dataset*

Cancer Waiting Times (CWT)

Diagnostic Imaging Dataset (DIDS)*

National Cancer Patient Experience Survey*

Wales (annual)

CaNISC or Cancer Information System

Patient Episode Database for Wales (PEDW)

Radiotherapy Data available in Canisc

Mortality data - Office for National Statistics (ONS)



GIG
CYMRU
NHS
WALES

Perfformiad a
Gwella
Performance and
Improvement

*Available in England on an annual basis only

@NATCAN_news

Patient reported outcome measures (PROMs)

- PROMs determine patients' views of their symptoms, functional status and health-related quality of life (QoL)
 - measure **safety** and **effectiveness** of care
- NPCA carried out a patient survey
 - What are the outcomes reported by men after radical treatment for prostate cancer?
 - **Views on experience of care**
- Questionnaire developed in consultation with clinical and patient representatives
 - **generic** (EQ-5D-5L) and **disease specific** (EPIC-26) validated PROMs instruments
 - **selected PREMs** questions from National Cancer Patient Experience Survey (CPES)
- Successful patient engagement – high response rates
 - Overall: survey sent to 60,817 men – 73% responded (44,355)
- Data from the National Cancer QoL survey carried out by NDRS is currently unavailable to NATCAN
 - Hopeful these data will be available in due course



Patient reported experience measures (PREMs)

What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England 

 Melanie Morris ^{1, 2}, Adrian Cook ¹,  Joanna Dodkins ¹, Derek Price ³, Steve Waller ¹, Syreen Hassan ², Arjun Nathan ¹, Ajay Aggarwal ², Heather Ann Payne ⁴, Noel Clarke ^{1, 5},  Jan van der Meulen ², Julie Nossiter ¹

- Variation in how care was experienced by men of different ages, ethnic and socioeconomic background
- PREMs are an important quality indicator and provide targeted information to hospitals of where improvements are needed in communication & support
- Patient involvement is key – co-authors


“It is not surprising to me that men in the higher risk group responded less favourably to the questions on whether their views on treatment were taken into account and whether they were involved as much as they wanted in care and treatment decisions. They would have felt less involved because, in order to attempt a cure, their clinicians would have lent towards those treatments which were likely to result, in their opinion, in a better outcome.”



Data Dashboards

Quarterly reporting provides information on:

- **Data quality (completeness)** of key data items captured in the rapid cancer registration data at NHS trust level
- Range of **performance indicators** at NHS trust and Cancer Alliance level



NATCAN
National Cancer Audit
Collaborating Centre

Select metric:

Percentage of people recorded as having i) breast-conserving surgery, or ii) mastectomy, within 12 months of diagnosis

Results



Indicator information

Methods



National Audit of Primary Breast Cancer - Quarterly Report (01-01-2022 to 31-12-2024)

Percentage of people recorded as having i) breast-conserving surgery, or ii) mastectomy, within 12 months of diagnosis at Guy's and St Thomas' NHS Foundation Trust



Performance is calculated using: number of people diagnosed with early breast cancer (stage 0-3A or "unknown"). — which are shown as the coloured bars in the case volume chart. These cases are used to calculate the quarterly data points and moving average shown in the performance chart.



NATCAN

National Cancer Audit
Collaborating Centre

NATCAN Annual State of the Nation Reports

- Provides a concise overview of care received across England and Wales
- Describe national patterns of care against measurable standards
- Provide five key recommendations for action
 - Accompanying provider-level results
- Patient summary developed with PPI Forums




National Ovarian Cancer Audit State of the Nation Report 2026

An audit of care received by women diagnosed with ovarian cancer between 1 January 2022 and 31 December 2023 in England and 1 January 2022 and 31 December 2024 in Wales.
Published June 2026

"The treatment you get, how quickly you get it, and how well you are supported is subject to far too much variation across England and Wales. NATCAN are doing an exceptionally thorough job of demonstrating that – it's our role as a clinical community to do something about it."

Richard Simcock, Chief Medical Officer, Macmillan Cancer Support






NATCAN

National Cancer Audit
Collaborating Centre

State of the Nation publications 2026/2027



NOCA Quality Improvement Intervention

The NOCA team is launching a Quality Improvement (QI) intervention in autumn 2025.

Our goal is to increase the **proportion of women diagnosed with ovarian cancer after an emergency admission who receive any treatment (surgery and/or chemotherapy).**


The NOCA is working in collaboration with the British Gynaecological Cancer Society (BGCS) to share best practice, please watch our webinar [here](#). In addition, all Gynaecological Cancer Systems in England and Wales will receive a feedback letter and short report from NOCA.

Please take a look at the poster below for more information:

[NOCA QI Intervention Poster](#)

[NOCA QI Intervention Response Log](#)

National Ovarian Cancer Audit: Quality Improvement intervention 2025




National Ovarian Cancer Audit
@NOCA_NATCAN

NOCA has launched a Quality Improvement intervention to help improve treatment for women diagnosed with ovarian cancer following emergency admission.

A huge thank you to all the trusts who have responded!

Find more details here on responses so far : buff.ly/AyiWGrc



Engagement with clinical community



NATCAN Audits Lunchtime Webinars
hosted by RCR, October & November 2025

2025 SotN webinar
State of the Nation Webinars 13.10.25
[Find out more information](#)

NATCAN Webinar:
Exploring Key Findings from the 2025 SotN Reports Part 2
@natcan-news
@NATCAN_news
13.10.2025
15.00 - 16.30 BST

State of the Nation (SotN) highlights from:

- NOGCA**
National Oesophago-Gastro Cancer Audit
- NPACA**
National Pancreatic Cancer Audit
- NAoMe**
National Audit of Metastatic Breast Cancer
- NAoPri**
National Audit of Primary Breast Cancer

Centre-level conferences & webinars

NHSE Cancer Manager
Conference, October 2025

National Cancer Audit Collaborating Centre (NATCAN) – Using data to improve patient outcomes

Julie Nossiter, Director of Operations
Sugeeta Sukumar, Quality Improvement Fellow
Verity Walker, Project Manager

14th October 2025

Driving improvements in cancer: Insights from the NATCAN (London Global Cancer Week)

Royal College of Surgeons, London School of Hygiene & Tropical Medicine, NHS England, HQIP, NDRS, GIG NHS, The Royal College of Radiologists

NATCAN: Driving improvements in Cancer

London Global Cancer Week
27th of November 2025

Ajay Aggarwal

MORE VIDEOS

L G C W
LONDON GLOBAL CANCER WEEK

@NATCAN_news

Engagement with clinical community



Members of the NAOpri team at the 2025 ABS Conference



NLCA Clinical Fellow Lauren Dixon with her prize-winning abstract at the BTOG Conference 2025



Nicola Fearnhead, NBOCA Surgery Lead, chairing the panel discussion on Close It Quick at the ACPGBI Annual Meeting

Audit team presentations at national conferences & workshops/webinars hosted by professional organisations



Kate Walker, NNHLA Senior Methodologist, at the British Society of Haematology's 65th Annual Scientific meeting.



Raghav Varma, NKCA Clinical Fellow, presenting at the BUG Annual Meeting



National Patient Data Awareness Day 2025

- Attended first use My data conference 2025
- Launch of National Patient Data Awareness Day
- NATCAN selected to present in Data Soapbox
‘Celebrating the use of patient data’

“We don’t use names or NHS numbers. But every number in our data represents a person – a life, a family, a story. And we have a responsibility to use that information with purpose, to make care better, fairer, and faster for everyone.”

Olivia Connor, National Oesophago-Gastric Audit (NOGCA) Clinical Fellow, speaking at the ‘Soapbox Competition’ at the inaugural National Patient Data Day conference

 **use MY data**
a trusted voice in patient data



Vikki Hart and Olivia O'Connor representing NATCAN at the 2025 National Patient Data Day conference



NATCAN: next steps

- **Strengthen engagement with clinical communities and people with lived experience**
- **Further innovations in reporting & feedback**
 - Further development of interactive dashboards will expand features of the dashboards
 - Launch central dashboard
 - Begin quarterly reporting in Wales
- **Stimulating improvement of cancer services**
 - Evaluation of QI intervention by each audit
 - QI tools for local teams to identify good practice / areas of weakness
 - QI workshops / webinars
- **And beyond...**
 - Re-tender for NATCAN beyond October 2027
 - Addition of other cancer types
 - Expand datasets – primary care data, PROMs
 - UK wide
 - Collaborations – national & international



Royal College
of Surgeons
of England
ADVANCING SURGICAL CARE

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



NHS
England



HQIP
Healthcare Quality
Improvement Partnership



NDRS
NATIONAL DISEASE REGISTRATION SERVICE



GIG
CYMRU
NHS
WALES

Perfformiad a
Gwella
Performance and
Improvement



NATCAN
National Cancer Audit
Collaborating Centre

NATCAN PPI (Patient & Public Involvement) Forums

Verity Walker, Centre Project Manager

22nd June 2026

Summary of PPI (Patient & Public Involvement) forums for Each Audit

- Consultative group, representing the patient's view
- Members are involved in the production of audit outputs including:
 - ✓ Patient & public information materials
 - ✓ Summaries of the annual State of the Nation reports.
 - ✓ Audit infographics to aid the dissemination of key information
 - ✓ Co-development and co-authorship of scientific papers that explore audit results.
- Have a key advisory role in developing the audit web pages
- Audit quality improvement goals, activities, and outputs



Recruitment Approach

- The audits primarily worked with patient charities to recruit members:
 - ✓ Liaised closely with patient charities and took a collaborative approach.
 - ✓ Charities tapped into their existing patient networks.
 - ✓ Some charities used their social media and pop-up adverts on their websites to reach a wider audience.
 - ✓ Sharing resources and expertise to support recruitment efforts (ToR, advert, expression of interest forms, and patient booklets).






NATCAN

National Cancer Audit
Collaborating Centre

Setting Up PPI Forums

- Undergoing recruitment with the patient charities
- Producing documentation
 - ToRs, recruitment adverts, welcome material (booklet, FAQs)
- Arranging the first group meeting
- Ensuring diverse representation across all groups (e.g. stage, treatment, regionally)
- Confirming the PPI Chair





NATCAN

National Cancer Audit
Collaborating Centre

Activities and Involvement

- Patient summaries of reports
- Website content (blogs, newsletters)
- Patient information & resources



National Ovarian Cancer Audit State of the Nation Patient and Public Report 2026

An audit of care received by women diagnosed with ovarian cancer between 1 January 2022 and 31 December 2023 in England and 1 January 2022 and 31 December 2024 in Wales.

Published June 2026

Receipt of any treatment (surgery and/or chemotherapy)
for women with emergency admission prior to diagnosis*

59.7% **E** England 2022 **61.3%**

70.1% **W** Wales 2023 **71.0%**

of women who had an emergency admission prior to ovarian cancer diagnosis in England (E) in 2023 and in Wales (W) in 2024 had any treatment recorded within three months of diagnosis.

Panpals Pancreas Patient Group open 'The Teale Room'




Karen Stead (pictured far right), is a key member of NPAC's Patient and Public Involvement (PPI) Forum and is a survivor of pancreatic cancer. She is also an active campaigner in raising awareness of this condition. Karen and other members of the Panpals Pancreas Patient Group, have recently undertaken a project to refurbish a room at St James's University Hospital in Leeds. Karen explains, "We wanted to refurbish a previously, cold and uninviting room at the Hospital, into a calm and comfortable space for 'difficult conversations' between patients and Consultants. This involved discussions with Leeds Teaching Hospitals NHS Trust and the Leeds Hospitals Charity and took 10 months to complete. The room refurbishment cost £5,000 and was funded by donations from friends and from collections from the funerals of those who sadly lost their lives to pancreatic cancer. We chose some lovely prints of Yorkshire scenes and of a local waterfall. We decided to name the room, 'The Teale room', after Marcelle Teale, who is incredibly friendly and helpful and is Secretary to Mr Andrew Smith (Co-Clinical Lead for NPAC) (pictured)". Our congratulations to Karen and to everyone involved in creating this lovely space!



Images kindly provided by the LTH medical illustrators.

The picture to the right shows the sequence of steps in a typical breast cancer pathway, from diagnosis to treatment, in English and Welsh hospitals.

Over the page you will find information on each of these steps in the pathway along with some prompts for questions you may find useful to ask.




"The power of data: how using statistical analysis will generate insights and identify best practice for the quality of care of people with a diagnosis of non-Hodgkin lymphoma."



A short blog prepared by NNHLA PPI Chair, Frank Burroughs.

BLOOD CANCER AWARENESS MONTH



Activities and Involvement

- Quality improvement (QI) interventions
 - Shaping QI priorities
 - Supporting QI activities
 - Events
- Website and data dashboard development




@NATCAN_news



Representation Overview

- We aim to have diverse representation across all groups
 - Geographical location
 - Stage
 - Gender
 - Age
 - Ethnicity
 - Treatment
- We keep current membership under review and address any gaps by undertaking further recruitment with support from our charity stakeholders





NATCAN

National Cancer Audit
Collaborating Centre

Next Steps...

- Reviewing representation & continued recruitment
- Working with PPI reps during retender for NATCAN
- Working with our centre level PPI group (PIN)
- Continuing to work closely with our patient charity stakeholders





NATCAN

National Cancer Audit
Collaborating Centre

Christine – living beyond pancreatic cancer





Royal College
of Surgeons
of England
ADVANCING SURGICAL CARE

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



NHS
England



HQIP
Healthcare Quality
Improvement Partnership



NDRS
NATIONAL DISEASE REGISTRATION SERVICE



GIG
CYMRU
NHS
WALES

Rhwydwaith
Cancer Cymru
Wales Cancer
Network



NATCAN
National Cancer Audit
Collaborating Centre

National Lung Cancer Audit Patient & Public Involvement Forum

Lauren Dixon
NLCA Clinical Fellow
22nd June 2026



NLCA
National Lung
Cancer Audit



Society for Cardiothoracic Surgery
in Great Britain and Ireland

NLCA@rcseng.ac.uk



NATCAN

National Cancer Audit
Collaborating Centre



NLCA

National Lung
Cancer Audit

— What is NLCA?

The National Lung Cancer Audit (NLCA) evaluates the patterns of care and outcomes for people with lung cancer in England and Wales, and to support NHS services to improve the quality of care for these individuals.

NLCA National Lung Cancer Audit


State of the Nation Report 2023

Results of the National Lung Cancer Audit for patients in England during 2021 and Wales during 2020-2021

Version 3: November 2023




www.natcan.org.uk/audits/lung/



NLCA@rcseng.ac.uk


Why do we need a PPI forum?

Before our PPI forum in 2023, NLCA was shaped by a wide range of expert input through the clinical reference group...



Why do we need a PPI forum?

Before our PPI forum in 2023, NLCA was shaped by a wide range of expert input through the clinical reference group...



Building the PPI forum





NLCA | National Lung
Cancer Audit

Patient and Public Involvement (PPI) Forum

Welcome Booklet



Introductory Pack


As well as this booklet, your pack should also include the following:

- Our most recent NLCA State of the Nation Report
- Our most recent NLCA Patient and Public Report
- Terms of Reference

Meetings



NLCA
National Lung
Cancer Audit



PPI Contribution to reports



National Lung Cancer Audit State of the Nation 2026

An audit of care received by people diagnosed with lung cancer between 1 January 2024 to 31 December 2024 in England and Wales.

Published February 2026



PPI Contribution to reports

💡 **PPI Question:** How can we help patients understand NLCA outputs?



This report was prepared by members of the NLCA project team

Neal Navani, NLCA Senior Clinical Lead	Clinical Effectiveness Unit, RCS England
John Conibear, NLCA Oncology Lead	Lauren Dixon, NLCA Clinical Fellow
Doug West, NLCA Thoracic Surgical Lead	Joanne Boudour, NLCA Senior Project Manager
	Faine Chan, NLCA Project Coordinator
	Adrian Cook, NLCA Senior Statistician
	Sarah Cook, NLCA Methodologist
	David Cromwell, NLCA Methodologist

We would like to thank and acknowledge the members of the National Lung Cancer Audit Patient and Public Involvement Forum and Roy Castle Lung Cancer Foundation for their guidance in producing this report.

Citation for this document:

National Lung Cancer Audit. State of the Nation Patient and Public report 2026 for patients and the public. London: Royal College of Surgeons of England, 2026.

State of the Nation Patient and Public Report 2026

Results of the National Lung Cancer Audit for people diagnosed with lung cancer in England and Wales during 2024
(Published 2026)




PPI Contribution to reports

💡 **PPI Question:** Can we present data in more meaningful ways?

Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)



Systemic anti-cancer therapy for Small Cell Lung Cancer in England



Diagnosis

41,544 patients were diagnosed with lung cancer in 2024:
39,409 in England
2,135 in Wales



74
years old

average age at diagnosis

Around 1 in 10 patients diagnosed had **never smoked**:



1 in 10
patients

2 in 5 patients had **late stage** (stage 4) lung cancer at the time of diagnosis

3 in 10 of patients were first diagnosed after going to an **emergency department** with symptoms:



3 in 10
patients

Lung cancer nurse specialists

9 in 10 patients were supported by a **lung cancer nurse specialist***



NLCA Target
9 in 10

*Information is missing for a third of patients in England

Treatment intending to cure lung cancer

15 in 20 patients with early stage (stage 1-2) Non-Small Cell Lung Cancer received treatment with **surgery** or **radiotherapy** intending to **cure**



NLCA Target
16 in 20

Surgery for Non-Small Cell Lung Cancer in England

1 in 5 patients with Non-Small Cell Lung Cancer had **surgery** for their lung cancer in England



NLCA Target
1 in 6

Surgery for Non-Small Cell Lung Cancer in Wales

1 in 6 patients with Non-Small Cell Lung Cancer had **surgery** for their lung cancer in Wales



NLCA Target
1 in 6

Systemic anti-cancer therapy for Small Cell Lung Cancer in England

7 in 10 patients with Small Cell Lung Cancer received treatment with **chemotherapy** in England



NLCA Target
7 in 10

Systemic anti-cancer therapy for Small Cell Lung Cancer in Wales

6 in 10 patients with Small Cell Lung Cancer received treatment with **chemotherapy** in Wales



NLCA Target
7 in 10

Systemic anti-cancer therapy for Non-Small Cell Lung Cancer

6 in 10 patients with advanced Non-Small Cell Lung Cancer received **systemic anti-cancer therapy** (including targeted therapy, chemotherapy & immunotherapy)



NLCA Target
7 in 10

Survival after lung cancer diagnosis

1 in 2 patients in England

survive 1 year after diagnosis

372
days
in England

average **survival** after lung cancer diagnosis

1 in 2 patients in Wales

350
days
in Wales

Contribution to research



PPI Question: Why do some patients receive treatment while others do not?

Open access

Original research


BMJ Oncology

Utilisation patterns of systemic anticancer therapy (SACT) in patients with advanced non-small cell lung cancer (NSCLC) in England

Lauren Kari Dixon ,^{1,2} Adrian Cook,¹ Sarah Cook,^{1,3} Ella Barber,¹ Joanne Boudour,¹ John Conibear,⁴ Douglas West,⁵ Neal Navani,^{6,7} David A Cromwell^{1,3}

Acknowledgements

We thank the members of the National Cancer Audit Collaborating Centre (NATCAN) for their support and guidance throughout this work, and the members of the National Lung Cancer Audit (NLCA) Patient and Public Involvement (PPI) Forum for their valuable insights, which have helped shape the interpretation and presentation of these findings.



Patient & public resources



PPI Question: What questions should I ask my healthcare team?



NLCA Questions to ask Healthcare Professionals

Navigating a lung cancer diagnosis and treatment can feel overwhelming. We have put together a list of questions that it might be helpful to ask healthcare professionals involved in your care for lung cancer. Not every question will be relevant to all patients and carers, and some may not be relevant at a particular meeting. However, this is a good starting point for planning out the questions you wish to ask your medical team during consultations. You can take these questions along with you to consultations and there is space to add any other questions you think of.

[List of questions – PDF version](#) ▶

[List of questions – word document version](#) ▶

NLCA Patient Questions to ask Healthcare Professionals

Navigating a lung cancer diagnosis and treatment can feel overwhelming. Below is a list of questions that it might be helpful to ask healthcare professionals involved in your care for lung cancer. Not every question will be relevant to all patients and carers, and some may not be relevant at a particular meeting. However, this is a good starting point for planning out the questions you wish to ask your medical team during consultations. You can take these questions along with you to consultations.

Information:

- What written information will I receive about the management of my cancer?
- Can I decide how much information I should receive about the management of my lung cancer?
- Can I bring a relative or friend to my consultations?
- When will someone explain to me what treatment options are available? Who will this be?
- Please can I have the contact details for relevant patient-support organisations?

Diagnosis:


- What type of lung cancer do I have?
- What stage is my lung cancer?
- Has my cancer already spread from my lungs? Is the cancer likely to spread in the future?
- What tests am I likely to have and what are they for?
- How long do the results of the tests take to come through?

Patient & public resources

💡 **PPI Question:** How can we help patients understand NLCA outputs?



**A patient guide to statistics used in
the National Lung Cancer Audit**



5. What a percentage means

Percentages help us describe information in a way that's easy to compare.

For example: If we say 30% of patients had surgery, that means 30 out of every 100 people with lung cancer received surgery.

Other examples:

- 5 out of 10 patients = 50% (or a half)



- 1 out of 4 patients = 25% (or a quarter)





Mean

The mean is what most people call the average. You add up all the numbers and then divide by how many numbers there are.

Example: If the ages of five patients are 60, 65, 68, 70, and 72, the mean age is $(60 + 65 + 68 + 70 + 72) \div 5 = 67$.



Median

The median is the middle number when all the numbers are arranged from smallest to largest.

Example: For the ages 60, 65, 68, 70, and 72, the median is 68 because it's in the middle. Half the patients are younger than 68, and half are older.

The median is often used for things like age because it isn't affected by very young or very old ages.



Mode

The mode is the number that appears most often in a group.

Example: If the ages are 60, 65, 65, 68, and 70, the mode is 65 because it appears twice.



Each of these numbers helps describe a group in a different way. Sometimes one is more useful than the others depending on the information.

10. Key Messages to Remember

- Statistics help us understand lung cancer care so we can improve it.
- They describe groups of people, not individuals.
- **You are not a number. Your care is personal.**

Contribution to quality improvement

💡 **PPI Question:** Does every patient have access to a lung cancer nurse specialist?



NLCA

National Lung
Cancer Audit



LUNG
CANCER
NURSING
UK

Improving Access to LCNS Care

National Lung Cancer Audit Quality Improvement Initiative, in collaboration with Lung Cancer Nursing UK

10 Steps to Improving Access to LCNS Care:



1. Review your data in the NLCA Dashboard

Review your local results in the [NLCA Dashboard](#): is there anything from the list below that can improve your service?

2. Train All Staff

Ensure every LCNS understands how to complete COSD fields accurately. Include training for new starters (e.g. Y1, Y3, Y4 categories).



3. Monthly Validation

Nominate an LCNS to validate data each month with cancer services support.

4. Check Caseloads

Review LCNS:patient ratio. Aim for $\leq 1:40$ (NOLCP recommendation).



5. Review Job Plans

Ensure weekly activity covers all clinical settings. Highlight gaps to management.

6. Build the Case

Develop business cases with managers to increase LCNS staffing to NOLCP levels.



7. Administrative Support

Introduce admin support so LCNSs can focus more time on clinical care.

8. Strengthen MDT Links

Communicate with the wider MDT about the LCNS role and its impact on quality care.



9. Collaborate with CNS Teams

Work with other CNSs to share knowledge, avoid duplication, and improve patient experience.

10. Patient Feedback

Run local patient surveys to identify gaps and address needs.



Together we can improve care

By working collaboratively, we can ensure that every patient with lung cancer benefits from the support of an LCNS.

Contact us:

natcan.org.uk/audits/lung
nlca@rcseng.ac.uk
lcnuk.org



"Think beyond the data. Think about what the data actually means."

Where next?



NLCA

National Lung
Cancer Audit





“The patient voice needs to be front and centre in the cancer treatment conversation, and I am convinced that the PPI teams in NATCAN ensure that this continues to be the case.”

Duncan, PPI Chair for the National Lung Cancer Audit (NLCA)



NATCAN

National Cancer Audit
Collaborating Centre

Frank Burroughs

Chair – PPI Forum

National NHL Audit – NATCAN



Volunteering with NATCAN has given me the opportunity to contribute to a project that is likely to have a lasting impact on the lives of NHL patients

Activities I have been involved with include:

- Attending and presenting at Quality Improvement events bringing all ten audits together
- Giving my experience as feedback for the patient and public version of the audit's annual State of the Nation report
- Writing a blog on the patient's perspective of data driven quality improvement in healthcare, and the future potential this offers
- Feeding back thoughts and ideas to help shape the latest version of the NATCAN dashboard
- Chairing the PPI Forum and engaging with other volunteers to make sure the patient voice influences the audit and helps to determine future priorities

Being involved in the audit is a highly rewarding experience – challenging and fun in equal measure – and none of it would be possible without the data!



Royal College
of Surgeons
of England
ADVANCING SURGICAL CARE

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



NHS
England



HQIP
Healthcare Quality
Improvement Partnership



NDRS
NATIONAL DISEASE REGISTRATION SERVICE



GIG
CYMRU
NHS
WALES

Perfformiad a
Gwellu
Performance and
Improvement



NATCAN
National Cancer Audit
Collaborating Centre

People Involvement Network – PIN

Presenter: Vikki Hart, Senior Project Manager

Date: Monday 22nd of June, 2026



people
involvement
network



people
involvement
network



NATCAN
National Cancer Audit
Collaborating Centre

What is PIN?

A new, exciting, **highly-collaborative and supportive space**, where a **community** of like-minded individuals, with extensive and varied, professional and personal, **lived-experience** of the impact of a cancer diagnosis, can **expand** on the excellent work being undertaken by the individual audit, PPI Forums.



people
involvement
network



NATCAN
National Cancer Audit
Collaborating Centre

WHY INITIATE A NEW NETWORK?



“The Network will be invaluable in helping to **facilitate collaborative working** and the **sharing of good practice** between audits, and in **supporting new work** on the horizon for NATCAN. I am looking forward to seeing what possibilities arise because of this important new initiative.”

Lesley Goodburn, PPI Chair for the National Pancreatic Cancer Audit (NPaCA).



people
involvement
network

MEMBERSHIP

Core Members Group

This currently consists of the Chairs of the current 10 National cancer audits sitting within NATCAN, and a small number of NATCAN representatives.

Future Expansion Plans

Expanded to include representation from:

- Charity partners
- National Patient-focussed organisations
- Funder representation
- Potentially other members of the public.



people
involvement
network

PIN ACTIVITIES TO DATE

- ✓ Discussed and agreed on a name and identify for the network
- ✓ Supported wider research activities e.g. providing feedback to HQIP
- ✓ Representing NATCAN at conferences/events e.g. Frank's support today
- ✓ Provided feedback on the design of the new NATCAN, Patient and Public Involvement focussed web pages – <https://www.natcan.org.uk/ppi>



NEXT STEPS/ACTIVITIES

- ✓ Second meeting of the group planned for August
- ✓ Develop a short, annual newsletter
- ✓ Establishing a social media presence
- ✓ Supporting wider research activities and future opportunities
- ✓ Providing feedback on the design of the NATCAN combined data dashboards planned for the Autumn
- ✓ Exploring opportunities for influencing policy
- ✓ Consideration given to expanding PIN membership
- ✓ Implementation of speaker programme plans



EXAMPLE SPEAKER PROGRAMME

Speaker	Example Topic
NHS England	Explaining the work of the Cancer Treatment Variation Group
NDRS	Explanation of data flows and how the data is processed
useMYdata	Why correctly acknowledging patient data matters
NATCAN	Past, Future and Present view of our work
PPI Chair	How to engage communities and raise awareness
Data Scientist	How we interpret data and present our results



people
involvement
network



NATCAN
National Cancer Audit
Collaborating Centre


Thank you!



Acknowledgements:

NATCAN PPI Forums, Project teams, Board, Executive, Stakeholders

Connect with us



@NATCAN_news